Left ventricular (LV) pressure overload leads to myocardial remodelling and reduced cardiac function. Both cardioprotective and deleterious effects have been attributed to SMAD2/3 (SMAD, small mothers against decapentaplegic) signalling, but the role of these important molecules in pressure overload remains unclear. The aim of this study was to examine the effects of SMAD2 inhibition on cardiac function and remodelling in mice subjected to aortic banding (AB), using a small molecule inhibitor (SM16) of SMAD2 signalling.
Introduction
Pressure overload of the left ventricle, as seen in patients with aortic stenosis and hypertension, induces myocardial remodelling with hypertrophy of cardiomyocytes and development of myocardial fibrosis. Untreated, this frequently leads to reduced cardiac function. 1 Both cardiomyocyte dysfunction 2 and changes in the extracellular matrix such as increased collagen synthesis 3 might explain reduced cardiac function in pressure overload. However, the therapeutic potential and specific role of the activation of various signalling molecules in remodelling and development of cardiac dysfunction following pressure overload are currently only partly known.
Increased stress to the myocardium induces production of mediators that might alter cardiac function. 4 -7 Cytokines seem to play a particularly important role in pressure overload. 1 Both acute and chronic myocardial dysfunction have been ascribed to the activation of tumour necrosis factor signalling. 8 Moreover, chronic fibrosisrelated diastolic dysfunction due to transforming growth factor-b (TGF-b) has been described. 9 The small mothers against decapentaplegic (SMAD) proteins are transcription factors that are activated by phosphorylation and mediate TGF-b superfamily signalling. 10 A role in myocardial remodelling has been suggested for several TGF-b superfamily members. However, both deleterious and cardioprotective effects have been attributed to the activation of the SMAD2/3 signalling system. 10 -13 Thus, whether activation of these signalling molecules leads to improved or reduced cardiac function remains unclear. SM16 is a novel small molecular inhibitor of activin like kinase (ALK) 4 and 5 (TGF-b receptor type I), which effectively reduces the phosphorylation of SMAD2. 14 This compound was developed to address the possible role of TGF-b/SMAD in fibrotic disease and cancer. It is available for oral administration and has previously been successfully administered to mice. 15 If SMAD2 mediates detrimental effects on the heart, such a drug might have therapeutic potential in patients with left ventricular (LV) pressure overload. The aims of the present study were to determine the role of SMAD2 signalling on cardiac remodelling and function in response to pressure overload in vivo, and whether this signalling system is inhibited by SM16 in isolated cardiomyocytes. This was examined by inhibiting the SMAD2 signalling system pharmacologically with SM16 in a mouse model of LV pressure overload and in isolated cardiomyocytes.
Methods

Animal experiments
Six-week-old C57BL/6 male mice (n ¼ 186) were subjected to 1 week banding of the ascending aorta (AB) or sham procedure, as previously described. 16 Isoflurane (2%) was used for anaesthesia. The adequacy of anaesthesia was monitored by observation of slow breathing, loss of muscular tone, and no response to surgical manipulation. Buprenorphine (0.36 mg/kg) was injected subcutaneously for post-operative analgesia.
Mice were randomized to receive either standard chow (STD) or chow formulated with SM16, a novel inhibitor of SMAD2 phosphorylation, 15 from 4 days before surgery. Surgery was performed blinded to chow. Total operative mortality was 32%, which was unaffected by type of chow administered. There were two late deaths from aortic rupture at the site of the ligature, as verified by autopsy. One AB died at day 6 and one sham died at day 5; both were treated with SM16. Animals were handled according to the Norwegian National Regulation on Animal Experimentation in accordance with the Norwegian Animal Welfare Act. The protocol was approved by the Norwegian National Animal Research Committee. The investigation conforms with Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes.
Echocardiography
Prior to sacrifice, 36 mice were examined by echocardiography using the Vevo770 system (VisualSonics, Toronto, Canada) for 2D and M-mode recordings. The VIVID7 system (GE Vingmed Ultrasound, Horten, Norway) with the i13L 14-MHz linear array transducer was employed for the measurement of blood flow and tissue velocities. Recordings were performed with the mice in the supine position, lying on a heated mattress with a heating lamp above, keeping the body temperature at 378C, while spontaneously breathing 1.75% isoflurane gas on a mask. Recordings were interpreted off-line. Both recordings and interpretations were performed blinded to chow. Maximal velocity across the aortic constriction was measured in all banded mice in the study ( Table 1 ) and mice with maximal velocity ,3 m/s, corresponding to a pressure gradient of 36 mmHg using the modified Bernoulli equation, were considered to have inadequate constriction and were excluded from the study (n ¼ 5).
SM16
The novel small molecular inhibitor of ALK4 and 5, SM16, was generously provided by Biogen Idec (Cambridge, MA, USA). SMAD2/3 are phosphorylated by TGF-b type I receptors (ALK4, ALK5, and ALK7 Inhibiting p-SMAD2 in pressure overload in in vivo animal experiments without demonstrating off-target effects (unpublished data, personal communication from Dr Leona E. Ling, Biogen Idec). This is in line with our in vitro data on cardiomyocytes (Supplementary material online, Table S1 ). SM16 was formulated into rodent chow (Research Diets, New Brunswick, NJ, USA) in the dose of 0.45 g SM16/kg chow. The pharmacokinetics of SM16 in mice following oral and parenteral administration has previously been described and 0.45 g SM16/kg chow gave a plasma concentration of 6.7 + 2.4 mmol/L and is considered the optimal dose with respect to efficacy and side effects. 15 
RNA extraction
RNA was extracted as previously described. 16 Briefly, total RNA was extracted using RNeasywMicro Kit (Qiagen). RNA quality was assessed using spectrophotometric (NanoDrop, ND-1000 Saveen Werner, Malmö , Sweden) and micro-fluidic analysis (2100 Bioanalyzer, Agilent Technologies, Palo Alto, CA, USA). Reverse transcription was performed with the iScript TM cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA).
Quantitative PCR analysis
The relative quantity of mRNA was assessed as previously described. 16 Briefly, TaqMan (Applied Biosystems, Foster City, CA, USA) assays were used with gene-specific primers (Supplementary material online, Table S2 ) (Applied Biosystems). qPCR was performed in a 7900 HT Fast-Real-Time PCR system (Applied Biosystems). The SDS 2.3 software (Applied Biosystems) was used to quantify the amount of genespecific RNA.
Protein isolation and immunoblotting
Protein from 25 mg of frozen left ventricle was extracted as previously described 18 and the protein concentration in the lysate was determined.
An equal amount of protein from each sample was applied and separated on 4 -15% SDS -PAGE before blotting the bands to PVDF membranes. The membranes were incubated with antibodies as described in Supplementary material online, Table S3 and visualized with ECL substrate (Bio-Rad). Quantification of the band intensity was performed using the ImageQuant TL software (Amersham Biosciences). Proteins were normalized to sham STD or control from each gel. Coomassie Blue staining 19 of the western blot membranes was used to visualize that protein loading and transfer was equal (Supplementary material online, Figures S1 and S2).
Myosin heavy chain isoforms
For the separation of myosin heavy chain (MHC) isoforms a and b, 60 mg of protein from each sample was loaded on SDS -PAGE gels containing 30% glycerol. The gels were electrophoresed for 24 h at 90 V, and bands were visualized with Sypro Ruby Protein Gel Stain (Lonza Rockland, Inc., Rockland, ME, USA). The gels were then scanned using Typhoon 9415 (Amersham Biosciences) and the image was displayed in ImageQuant (Amersham Biosciences) for quantification. Identification of the MHC isoform bands was based on previously reported separations of MHC isoforms in gels containing 30% glycerol. 20 
Analysis of collagen content
The content of hydroxyproline was analysed using high-performance liquid chromatography, as previously described. 16 Briefly, tissue samples from the left ventricle or lung were hydrolysed in 6 M HCl and vacuumdried. Samples were then reconstituted in AccQ-Fluor borate buffer, before derivatization by addition of AccQ-Fluor reagent (Waters Corporation Milford, MA, USA). Finally, hydroxyproline content was determined by fluorescence following high-performance liquid chromatography, using a 20 × 3.9 mm Sentry Guard column (Nova-Pak C18 bonded silica) connected to a 150 × 3.9 mm AccQ-Tag reversed-phase column (both from Waters), in agreement with the manufacturer's procedure. Elution of myocardial hydroxyproline from tissue samples was verified and quantified by co-elution with known amounts of derivatized hydroxyproline standards (Fluka, Buchs, Switzerland). The relation of tissue hydroxyproline content to collagen has previously been reported. 21 
Analyses of Ca 21 handling
Anaesthetized mice (2% isoflurane) were sacrificed by cervical dislocation, and hearts were rapidly excised. Cardiomyocytes were then isolated from the left ventricle as described previously. 22 
Cardiomyocyte culture
Cardiomyocytes were isolated from 1 -3-day-old Wistar rats as previously described. 23 Following 24 h of serum starvation, cells were stimulated with TGF-b1 (10 ng/mL, Millipore) for 2 or 48 h. Cells were preincubated with SM16 (5 mM, Biogen Idec) or vehicle for 60 min prior to TGF-b1 exposure. For protein analyses, cells were lysed using Bio-Plex TM Cell Lysis Kit (Bio-Rad) according to the manufacturer's instructions. RNA was isolated as described above.
Multiplex protein analysis
A multiplex protein assay (Bio-Plex, Bio-Rad) was used for analysing levels of phosphorylated and total proteins (Akt, ERK1/2, IkB-a, and JNK) from cardiomyocyte lysates according to the manufacturer's instructions.
Statistical analyses
Data are presented as mean + SEM. Differences between groups were analysed by two-way ANOVA, using the Holm-Sidak method for the correction of multiple comparisons. Student's t-test or Mann-Whitney rank-sum test was used for comparison between two groups. Linear regression was used to examine the relation between two continuous variables. x 2 test was used to analyse operative mortality by chow.
Data were transformed by natural logarithm where appropriate. We used P ≤ 0.05 as the level of statistical significance. SigmaPlot 10.0 (Systat Software, Inc., San Jose, CA, USA) was used for the analyses.
Results
SMAD signalling
AB led to a three-fold increase in SMAD2 phosphorylation (p-SMAD2) that was attenuated by SM16 ( Figure 1A) . Phosphorylation of SMAD3 was not increased ( Figure 1B) . Total SMAD2 and SMAD3 were unchanged on both mRNA ( Table 2 ) and protein levels ( Figure 1C and D) . SMAD4 and SMAD7 protein levels were not altered by SM16 in AB mice ( Table 3 and Supplementary material online, Figure S1 ), but mRNA expression of both signalling molecules were reduced by SM16 ( Table 2) . As SM16 at higher concentrations in a biochemical in vitro assay may inhibit P38 and Raf in addition to ALK4 and ALK5, levels of total and phosphorylated P38 and Raf were analysed. However, there were no differences between groups in the levels of total or phosphorylated P38 or Raf ( Table 3 and Supplementary material online, Figure S1 ). Stimulating rat cardiomyocytes with TGF-b1 for 2 h induced SMAD2 phosphorylation, which was inhibited by SM16 ( Figure 1E and F and Supplementary material online, Figure S2 ). Off-target activity of SM16 was not evident in cardiomyocytes examined by multiplex analysis of phosphorylated and total Akt, ERK1/2, IkB-a, and JNK (Supplementary material online, Table S1 ).
SM16 preserves cardiac function during pressure overload
Treatment with SM16 significantly preserved cardiac function, which was reduced following AB ( Figure 2) . In banded mice, SM16 improved fractional shortening by 38% (P ≤ 0.05), indicating improved systolic function (Figure 2A) , and decreased mitral flow deceleration by 28% (P ≤ 0.05), which indicates improved diastolic function ( Figure 2B) . The beneficial effects of inhibiting SMAD2 signalling were further supported by inverse correlations between p-SMAD2 levels and peak systolic and diastolic tissue velocities ( Figure 2C and D) . AB increased lung weight by 21% (P ≤ 0.05) and wet/dry lung weight ratio by 10% (P ≤ 0.05), which suggests pulmonary congestion ( Figure 3A and B). Lung collagen, however, was unaltered ( Table 3) . Lung weight correlated positively to mitral flow deceleration (R ¼ 0.49, P ¼ 0.001) and negatively both to fractional shortening (R ¼ 20.28, P ¼ 0.04) and systolic tissue velocity (R ¼ 20.37, P ¼ 0.01), further supporting the association between increased lung weight and cardiac dysfunction. The increase in lung weight was completely abolished by SM16 ( Figure 3A) , indicating substantial reduction in pulmonary congestion by SM16 treatment. As expected, cardiomyocyte hypertrophy was evident following AB, with 38% increased cell width, 11% increased cell length, and 58% increased cell area ( Figure 4A , B, and C ). This response to AB was significantly reduced by SM16. In line with this observation, LV mRNA expression of ANP and BNP was also attenuated by SM16 ( Figure 3C and D) . SM16 did not, however, affect total LV weight ( Figure 4D ). There was a trend towards an increased wet/dry LV weight ratio by 19% in AB SM16 mice (Supplementary material online, Table S4 ), suggesting alterations in non-cardiomyocytes or extracellularly. Chow consumption and body weight were equal in all groups (Supplementary material online, Table S4 ).
SM16 improves Ca 21 handling
In the left ventricle, both mRNA and protein levels of sarcoplasmic reticulum calcium ATPase 2 (SERCA2) were reduced following AB (by 44 and 26%, respectively; P ≤ 0.05 for both) ( Figure 5A and B). This SERCA2 reduction was attenuated by SM16 ( Figure 5A and B).
There was an inverse correlation between SERCA2 protein levels and lung weight ( Figure 5C ). In isolated rat cardiomyocytes, SMAD2 signalling induced by TGF-b1 stimulation led to reduced SERCA2 mRNA levels, whereas SM16 prevented this downregulation of SERCA2 ( Figure 5D ). In cardiomyocytes isolated from AB mice, cells from SM16-treated mice exhibited a more rapid decline of Ca 2+ transients compared with cells from STD mice ( Figure 6A and B) , which is consistent with enhanced SERCA2 function. In sham-operated mice, Ca 2+ transients were not altered by SM16 (Figure 6B-D) . Protein levels of the Na + /Ca 2+ exchanger (NCX) were increased from AB, although there was no effect of SM16 (Table 3 and Supplementary material online, Figure S1 ). Phosphorylation of phospholamban was not increased by SM16 (Table 3 and Supplementary material online, Figure S1 ). Table 2) . On the protein level, however, a-MHC was 68% increased (P ≤ 0.05) and b-MHC was 80% increased (P ≤ 0.05) in SM16-treated AB mice compared with sham ( Table 3) . In STD mice, there was a trend towards a 26 and 30% increase, respectively, however not reaching statistical significance. The levels of MHC isoforms did not correlate with cardiac function. Both TGF-b and growth differentiation factor-15 (GDF-15) have been reported to be of importance in the heart and have been suggested to induce SMAD2/3 signalling, 12, 13 and SM16 also attenuated the increased LV mRNA expression of TGF-b1, TGF-b2, and GDF-15 ( Table 2) . LV protein levels of anti-apoptotic Bcl-2, pro-apoptotic Bax, and caspase-3 were not significantly different in any group (Table 3) . This suggests that apoptosis is not an important factor in our study.
SM16 attenuates collagen mRNA levels
LV mRNA levels of collagen types I, III, VIII, and XV were four-to nine-fold increased by AB (P ≤ 0.05). This increase was attenuated by SM16 ( Table 2) . Protein levels of myocardial collagen were not increased after 1 week of AB as was demonstrated by highperformance liquid chromatography measurements of hydroxyproline. SM16 did not alter myocardial collagen content at this time point (Table 3) . In stimulated cardiomyocytes, TGF-b increased mRNA expression of collagen type I, but not type III (Supplementary material online, Table S5 ). This increase was attenuated by SM16.
Discussion
We have studied the cardiac effects of SMAD2 signalling during pressure overload in mice by using the novel pharmacological inhibitor SM16. Following AB, we found increased LV phosphorylation of SMAD2, but not SMAD3. SM16 effectively attenuated the phosphorylation of SMAD2 and significantly improved in vivo cardiac function in banded mice, as measured by echocardiography. Moreover, SM16 abolished the increase in lung weight following pressure overload, further supporting a beneficial effect on pulmonary congestion and cardiac function. In line with this, inhibiting SMAD2 phosphorylation also attenuated mRNA expression of the foetal genes ANP, BNP and a-skeletal actin. AB induced cardiomyocyte hypertrophy, which was attenuated by SM16 treatment. SM16 also prevented downregulation of SERCA2 following AB, inducing a more rapid decline of Ca 2+ transients. In rat cardiomyocyte cultures, TGF-b1 stimulation increased SMAD2 phosphorylation and reduced mRNA expression of SERCA2, whereas this was normalized by treatment with SM16, further supporting our in vivo findings. SMAD2 and SMAD3 are important intracellular signalling molecules. 10 Both are phosphorylated by ALK4 or ALK5 and mediate signalling by ligands in the TGF-b superfamily. 10 Upon phosphorylation, SMAD2 or SMAD3 forms a complex with SMAD4, translocates to the nucleus, and regulates transcription. 24 Both cardioprotective and deleterious effects have been attributed to the SMAD2/3 signalling system, 10, 12, 25 but the role of these important signalling molecules in pressure overload is unclear. To further examine this issue, we employed the SMAD2 inhibitor SM16. SM16 has, in a previous study, been tested in a biochemical in vitro assay against 60 different kinases, including ALK1 and ALK6, and apart from inhibition of ALK4 and ALK5, only weak inhibitory activity against P38 and Raf was demonstrated. 14 A role in promoting cardiac fibrosis during pressure overload has been reported for P38, 26 and activation of Raf-MKK-ERK1/2 has been suggested to contribute to cardiomyocyte hypertrophy. 26 In the present study, however, we did not find increased phosphorylation of P38, Raf, or SMAD3 after AB. TGF-b is known to induce phosphorylation of SMAD2, and in TGF-b1-stimulated cardiomyocytes, SM16 effectively inhibited phosphorylation of SMAD2, although off-target activity was not observed. Hence, we attribute the observed effects of SM16 mainly to the inhibition of SMAD2 signalling. Thus, pharmacological inhibition of SMAD2 phosphorylation, as in our study, might be a feasible strategy for investigating the role of p-SMAD2 in pressure overload. In the present study, pressure overload led to reduced cardiac function. This reduction was improved by SM16, as echocardiographic measures of systolic and diastolic function were improved. Furthermore, the increased lung weight and wet/dry lung weight ratio observed following AB was abolished by SM16, which indicates prevention of pulmonary congestion. In accordance with this, SM16 attenuated the increase in LV mRNA of the foetal genes a-skeletal actin, b-MHC, ANP, and BNP. 27, 28 SMAD2 has previously been shown to modulate the foetal gene alterations induced by leukaemia inhibitory factor in cardiomyocyte cultures. 29 In our study, AB induced cardiomyocyte hypertrophy, which was reduced by SM16, suggesting a possible role for TGF-b/SMAD signalling in cardiomyocytes. In a recent study using a rat model of myocardial infarction, administration of an ALK5 inhibitor prevented cardiomyocyte hypertrophy and attenuated cardiac dysfunction. 30 Our data demonstrate a clear antihypertrophic effect of SM16 on cardiomyocytes; however, LV weight was unaltered by SM16. Discrepancy between cardiomyocyte hypertrophy and heart weight has also been seen in other studies. In a paper by Xu et al., 12 AB in GDF-15 null mice led to increased heart weight/body weight compared with WT, although cardiomyocyte size was not enhanced. Total LV collagen was unaltered in our study; however, there was a trend towards increased wet/dry LV weight in AB SM16 mice, which might suggest that increased water content may contribute to the discrepancy between cardiomyocyte hypertrophy and LV weight. Reduction in LV SERCA2 has been reported following pressure overload, 31, 32 and transgenic SERCA2a mice are protected from cardiac dysfunction following AB. 33 Therefore, reduced SERCA2 levels might be an important mechanism for myocardial dysfunction in pressure overload. In our study, there was a 26% reduction in LV SERCA2 protein following AB, whereas this reduction was abolished in SM16-treated mice. Furthermore, LV SERCA2 protein levels correlated negatively with lung weight, indicating an association between SERCA2 levels and cardiac function. Diastolic dysfunction has been Inhibiting p-SMAD2 in pressure overload suggested to be an important mechanism for pulmonary congestion. 34, 35 The mechanism for improved diastolic function seen in our study might be due to enhanced removal of Ca 2+ from the cytosol during early diastole. SERCA2 is a major contributor to the diastolic removal of cytosolic Ca 2+ , which is important for myocardial relaxation. 36 Reduced SERCA2 function following pressure overload has been attributed to a quantitative reduction of SERCA2. 31, 32 In our study, phosphorylation of phospholamban was not increased by SM16 treatment, supporting the notion that improved Ca 2+ handling in SM16-treated mice is due to maintained SERCA2 protein levels and not to increased SERCA2 pump activity. The normalization of SERCA2 levels combined with the enhanced Ca 2+ transient decay in SM16-treated mice suggests that improved Ca 2+ removal from cytosol might be an explanation for the improved diastolic function in AB mice treated with SM16. A compensatory increase in NCX, as was seen following AB, might also potentially improve Ca 2+ removal from the cytosol during diastole. However, NCX levels were not altered by SM16 treatment. As AB SM16 mice had both increased NCX and preserved SERCA2 levels, this may explain the fact that Ca 2+ transient decay was preserved following AB and enhanced in SM16-treated AB mice. The mechanisms responsible for the downregulation of SERCA2 in heart failure remain unknown. In our study, there was reduced SERCA2 mRNA expression following TGF-b1 stimulation of neonatal rat cardiomyocytes, which was prevented by SM16. We found increased SMAD2 phosphorylation from TGF-b1, which was inhibited by SM16, without off-target activity being demonstrated. This suggests that TGF-b/SMAD2 signalling mediates downregulation of SERCA2. Thus, it seems that SM16 may improve cardiac function in pressure overload by attenuating the reduction of LV SERCA2 and improving Ca 2+ homeostasis in cardiomyocytes.
A role for SMAD2/3 signalling in fibrosis has also been suggested 37 -39 and post-infarction myocardial fibrosis was attenuated using an ALK5 inhibitor in rats. 30 In our study, SM16 attenuated the increased expression of collagen mRNA 1 week after AB. At this early time point, AB did not increase myocardial collagen on the protein level, as has also been reported by others. 40 Thus, we find it unlikely that potential effects on collagen synthesis may explain the functional differences observed in our study. This finding may support our conclusion that SM16 has a direct effect on cardiomyocytes to prevent dysfunction in pressure overload during the early phase of myocardial remodelling. Apoptosis has also been suggested as a mechanism contributing to reduced cardiac function. However, apoptosis has been reported to be minimal after 1 week of AB in mice 38, 40 and apoptosis signalling seemed to be unaltered in the present study.
In conclusion, we report for the first time that in LV pressure overload, pharmacological inhibition of SMAD2 signalling by SM16 preserves cardiac function. Inhibition of this signalling system by SM16 was also verified in isolated cardiomyocytes. We suggest beneficial effects of SM16 on cardiomyocyte Ca 2+ handling due to prevention of SMAD2-mediated downregulation of SERCA2, as the possible mechanism.
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